Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
13. Oktober 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today...
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
12. Oktober 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity...
Adagio Therapeutics Announces Corporate Name Change to Invivyd
12. September 2022 07:00 ET
|
Adagio Therapeutics, Inc.
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission...
Adagio Therapeutics to Participate in Upcoming Investor Conferences
06. September 2022 16:01 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
15. August 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and...
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
05. Juli 2022 07:26 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
01. Juli 2022 06:30 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports First Quarter 2022 Financial Results
13. Mai 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be...
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
14. April 2022 07:45 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Mengumumkan ADG20 (adintrevimab) adalah Antibodi Monoklonal Pertama untuk Memenuhi Titik Akhir Utama dengan Kepentingan Statistik Merentas Profilaksis dan Rawatan Pra dan Pos Pendedahan untuk COVID-19 dan Merancang untuk Mendapatkan Kebenaran Penggunaan Kecemasan A.S
31. März 2022 17:01 ET
|
Adagio Therapeutics, Inc.
Risiko COVID-19 bergejala telah dikurangkan sebanyak 71% berbanding plasebo dalam profilaksis pra-pendedahan dan 75% berbanding plasebo dalam profilaksis selepas pendedahan Risiko kemasukan ke...